Compare WULF & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WULF | IONS |
|---|---|---|
| Founded | 1952 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.6B |
| IPO Year | 1999 | 1996 |
| Metric | WULF | IONS |
|---|---|---|
| Price | $11.59 | $27.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 25 | 25 |
| Target Price | $25.52 | ★ $67.83 |
| AVG Volume (30 Days) | ★ 42.9M | 4.1M |
| Earning Date | 11-06-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $168,455,000.00 | N/A |
| Revenue This Year | $43.46 | N/A |
| Revenue Next Year | $257.90 | $26.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.28 | N/A |
| 52 Week Low | $9.51 | $26.55 |
| 52 Week High | $29.84 | $86.74 |
| Indicator | WULF | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 22.17 |
| Support Level | $10.31 | N/A |
| Resistance Level | $13.56 | $46.07 |
| Average True Range (ATR) | 1.24 | 1.99 |
| MACD | 0.09 | -0.74 |
| Stochastic Oscillator | 50.52 | 2.59 |
TeraWulf Inc develops and operates large-scale digital infrastructure designed for AI and high-performance computing workloads. The Company owns and operates energy infrastructure across key U.S. power markets, providing large-scale, contiguous power capacity for next-generation compute. Its strategic sites offer direct grid connectivity and, in select locations, integrated generation, creating a foundation for scalable compute infrastructure. Built on deep expertise in energy markets and grid integration, TeraWulf approaches compute infrastructure from the foundation up- securing power, developing scalable sites, and operating with disciplined execution.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).